Regend Therapeutics
Latest round
- Series C
Last raised
- Feb 2026
Total raised
- $52M
Investors
- 14
About Regend Therapeutics
, trading as Regend Therapeutics, is a medical company that engages in the developing regenerative medicine products. In 2016, the company built GMP production bases in Shanghai and Suzhou. In 2017, the company established Zhejiang Jiangnan Stem Cell Research Institute., Ltd. In 2019, the company's bronchial basal lamina cells passed the inspection of the China Academy of Food and Drug Control. Prof. Wei Zuo, the founder, president and chief scientist of the company, worked in the laboratory of G Palade-M Farquhar, a Nobel Prize winner in physiology and medicine. The company's main products include Regend001, Regend007 and Regend005, etc. Regend001 is an autologous lung precursor cell suitable for the treatment of chronic obstructive pulmonary disease COPD, idiopathic pulmonary fibrosis IPF and interstitial lung disease. The company's research areas include adult stem cell isolation and expansion, stem cell therapy and renal regenerative medicine. The company’s revenue is generated by providing cell gene therapy products.
Who invested in Regend Therapeutics
14 investors across 6 rounds
See all investors in Regend Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Questions about Regend Therapeutics
Who invested in Regend Therapeutics?
Regend Therapeutics has 14 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Regend Therapeutics raised?
Regend Therapeutics has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Regend Therapeutics last raise money?
Regend Therapeutics's most recent round on record is a Series C, in Feb 2026.
What does Regend Therapeutics do?
, trading as Regend Therapeutics, is a medical company that engages in the developing regenerative medicine products.
Where is Regend Therapeutics headquartered?
Regend Therapeutics is headquartered in Suzhou, China.
Which VCs invest in companies like Regend Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Regend Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Regend Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.